Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR)

Sumitomo Mitsui Trust Group Inc. lessened its stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 14.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,928 shares of the company’s stock after selling 7,711 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.43% of Burning Rock Biotech worth $198,000 at the end of the most recent reporting period.

Separately, Citadel Advisors LLC purchased a new position in shares of Burning Rock Biotech during the 4th quarter valued at approximately $83,000. 30.03% of the stock is owned by institutional investors and hedge funds.

Burning Rock Biotech Trading Up 4.5%

Burning Rock Biotech stock opened at $3.38 on Monday. The stock has a market cap of $36.32 million, a P/E ratio of -1.79 and a beta of 0.75. The stock has a 50 day moving average of $3.07 and a 200-day moving average of $4.75. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $2.18 and a 52 week high of $7.90.

Burning Rock Biotech (NASDAQ:BNR) last released its earnings results on Friday, June 6th. The company reported ($0.17) EPS for the quarter. The business had revenue of $18.34 million for the quarter. Burning Rock Biotech had a negative net margin of 45.41% and a negative return on equity of 38.33%.

Burning Rock Biotech Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.